RBC Capital lowered the firm’s price target on Zimmer Biomet to $120 from $130 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results. The firm’s industry checks suggest that Q3 underlying utilization trends were positive despite typical summer seasonality driving a sequential step-down in elective procedures, the analyst tells investors in a research note. Investor sentiment is also positive for MedTech stocks going into the earnings season, and investors are likely to continue to chase winners and catalyst-driven names into year-end, RBC added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $126 from $134 at BTIG
- Zimmer Biomet price target lowered to $110 from $113 at Evercore ISI
- Zimmer Biomet management to meet with BTIG
- Omnicell names Nnamdi Njoku as new COO
- FDA issues alert for increased risk of fracture after surgery with CPT System